-risk marker would likely shift the paradigm of managing DCIS to that used for managing atypical ductal hyperplasia (ADH) or lobular carcinoma in situ, limiting treatment to excisional biopsy alone, with only consideration of risk-reducing prophylaxis with
Search Results
Renaming Ductal Carcinoma in Situ: Would Removing “Carcinoma” Reduce Overtreatment?
Sara H. Javid, L. Christine Fang, Larissa Korde, and Benjamin O. Anderson
Characterization of Prostate Cancer in a Functional Eunuch
John J. Stocking, Michael V. Fiandalo, Elena A. Pop, John H. Wilton, Gissou Azabdaftari, and James L. Mohler
prostatic hyperplasia (BPH), or CaP. Figure 3. AR and AR-regulated expression in BP and CaP tissues: gene (A) and protein (B–G; original magnification x40). Abbreviations: AR, androgen receptor; BP, benign prostate; CaP, protate cancer; PSA
Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation
Juliana E. Hidalgo-López, Rashmi Kanagal-Shamanna, L. Jeffrey Medeiros, Zeev Estrov, C. Cameron Yin, Srdan Verstovsek, Sergej Konoplev, Jeffrey L. Jorgensen, Mohammad M. Mohammad, Roberto N. Miranda, Chong Zhao, John Lee, Zhuang Zuo, and Carlos E. Bueso-Ramos
myelofibrosis (MF). 3 Bone marrow (BM) specimens from these patients usually show characteristic findings, including atypical megakaryocytic hyperplasia with or without reticulin fibrosis. JAK2 V617F mutation also has been reported in chronic myelomonocytic
Safety and Efficacy of FOLFOX Followed by Cetuximab for Metastatic Colorectal Cancer With Severe Liver Dysfunction
Raymond Elsoueidi, Jessica Craig, Hesham Mourad, and Elie M. Richa
. 14. Rubbia-Brandt L Lauwers GY Wang H . Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis
Neuroendocrine Tumors
Matthew H. Kulke, Al B. Benson III, Emily Bergsland, Jordan D. Berlin, Lawrence S. Blaszkowsky, Michael A. Choti, Orlo H. Clark, Gerard M. Doherty, James Eason, Lyska Emerson, Paul F. Engstrom, Whitney S. Goldner, Martin J. Heslin, Fouad Kandeel, Pamela L. Kunz, Boris W. Kuvshinoff II, Jeffrey F. Moley, Venu G. Pillarisetty, Leonard Saltz, David E. Schteingart, Manisha H. Shah, Stephen Shibata, Jonathan R. Strosberg, Jean-Nicolas Vauthey, Rebekah White, James C. Yao, Deborah A. Freedman-Cass, and Mary A. Dwyer
, because these tumors are prone to rupture. 140 , 141 Benign hyperaldosteronism is much more common and can be caused by a unilateral adrenal adenoma or bilateral adrenal hyperplasia. Adrenal vein sampling for aldosterone is considered the standard for
NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer
Barbara Burtness, Milan Anadkat, Surendra Basti, Miranda Hughes, Mario E. Lacouture, Joan S. McClure, Patricia L. Myskowski, Jennifer Paul, Clifford S. Perlis, Leonard Saltz, and Sharon Spencer
. 46 El-Abaseri TB Putta S Hansen LA . Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor . Carcinogenesis 2006 ; 27 : 225 – 231 . 47 Luu
Challenges in the Histopathologic Diagnosis of Histiocytic Neoplasms
Karen L. Rech and Rong He
by histiocytes and hyperplasia of lymphocytes and plasma cells within the lymph node parenchyma. Confirmation of the RDD phenotype is necessary to distinguish RDD from nonspecific reactive histiocytes within the sinuses (sometimes called “sinus
Use of Nomograms for Early Detection in Prostate Cancer
Devon C. Snow and Eric A. Klein
prostatic hyperplasia as a function of age, volume and ultrasonic appearance of the prostate . J Urol 1997 ; 157 : 2160 – 2165 . 17. Garzotto M Hudson RG Peters L . Predictive modeling for the presence of prostate carcinoma using clinical
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
Dirk Mehrens, Kristina K.M. Kramer, Lena M. Unterrainer, Leonie Beyer, Peter Bartenstein, Matthias F. Froelich, Fabian Tollens, Jens Ricke, Johannes Rübenthaler, Nina-Sophie Schmidt-Hegemann, Annika Herlemann, Marcus Unterrainer, and Wolfgang G. Kunz
hyperplasia in the United States . J Manag Care Spec Pharm 2016 ; 22 : 1204 – 1214 . 9. U.S. Department of Veterans Affairs, Office of Procurement, Acquisition, and Logistics . Pharmaceutical prices . Accessed September 1, 2022. Available at: https
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Nadeem Abu-Rustum, Catheryn Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susana M. Campos, Junzo Chino, Hye Sook Chon, Christina Chu, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Robert Giuntoli II, Ernest Han, Jordan Holmes, Brooke E. Howitt, Jayanthi Lea, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Mirna Podoll, Ritu Salani, John Schorge, Jean Siedel, Rachel Sisodia, Pamela Soliman, Stefanie Ueda, Renata Urban, Stephanie L. Wethington, Emily Wyse, Kristine Zanotti, Nicole R. McMillian, and Shaili Aggarwal
, it may also be selectively used for young patients with endometrial hyperplasia who desire fertility preservation. The guidelines include an algorithm for fertility-sparing therapy in selected patients with biopsy-proven grade 1 (preferably by D
